ACUTE MYELOID LEUKEMIA (AML)

This study tested whether adding venetoclax to azacitidine helps people with untreated acute myeloid leukemia (AML) live longer. About 443 adults who couldn't have standard chemo took part. Two-thirds got the combo, one-third got a placebo plus azacitidine. The goal was to see if…

This phase 3 study tested whether adding venetoclax to low-dose chemotherapy helps older or frail adults with acute myeloid leukemia (AML) live longer. The trial included 211 people who could not tolerate strong chemotherapy. Results showed that the combination improved overall s…

This study tested a new drug, gilteritinib, combined with a standard medicine (azacitidine) in 183 adults newly diagnosed with acute myeloid leukemia (AML) who have a specific gene change (FLT3 mutation) and cannot receive intensive chemotherapy. The goal was to see if the combin…

This study looked at 98 adults with acute myeloid leukemia (AML) in their first remission who received a stem cell transplant from a matched sibling, matched unrelated donor, or half-matched family donor. All patients got the same chemotherapy before transplant. The goal was to s…

This study looked at how a combination of two drugs, ivosidenib and azacitidine, affects the quality of life and health of adults with a specific type of acute myeloid leukemia (AML) that has an IDH1 mutation. The 8 participants could not receive standard chemotherapy. The main g…

This study tested whether a combination of two drugs, venetoclax and azacitidine, can help adults with acute myeloid leukemia (AML) stay in remission after standard chemotherapy. The goal was to find the safest dose and see if it prevents the cancer from coming back. The study in…

This study tested whether adding a drug called pevonedistat to the standard two-drug therapy (venetoclax and azacitidine) helps adults newly diagnosed with acute myeloid leukemia (AML) who are not healthy enough for intensive chemotherapy. About 164 participants received either t…

This early-stage study tested a new drug called PRT2527, alone or combined with other drugs (zanubrutinib or venetoclax), in 86 people with blood cancers that returned or didn't respond to standard treatments. The main goals were to find a safe dose and check for side effects. Re…

This study tested a combined bone marrow and kidney transplant from a partially matched related donor for 10 people with both a blood disorder and chronic kidney disease. The goal was to treat both conditions and possibly reduce the need for lifelong anti-rejection drugs after th…

This study tracked 150 adults in South Korea with acute myeloid leukemia (AML) who were prescribed venetoclax tablets for the first time. Researchers monitored side effects and how well the drug controlled the cancer over about 7 months. The goal was to see how venetoclax works i…

This completed study gathered real-world information from 112 adults in France with acute myeloid leukemia (AML) who were in remission and taking oral azacitidine as maintenance therapy. Researchers tracked how long patients stayed relapse-free, overall survival, and treatment pa…

This study looked at 113 adults in Italy with certain types of acute myeloid leukemia (AML) who were treated with Vyxeos liposomal as part of their normal care. Researchers tracked how many patients achieved complete remission without signs of the disease after treatment. The goa…